Top Story Today
A Melanoma Drug Got Rejected Twice Despite Data the FDA Itself Called Breakthrough-Worthy
The FDA issued its second Complete Response Letter for Replimune's melanoma therapy RP1, rejecting the drug despite a 33% response rate and median response duration topping two years in patients who had already failed standard treatment. The culprit isn't the drug's efficacy; it's the trial design. IGNYTE was a single-arm study with no control group, and the FDA is making it crystal clear that impressive results without a randomized comparison no longer pass muster for accelerated approval. Replimune has a Phase 3 randomized trial running, but early data from it wasn't enough to save the single-arm submission.
Why it matters: This is the clearest signal yet that the FDA's era of accepting single-arm oncology trials for accelerated approval is ending. Every biotech running a cancer study without a control group just got put on notice.
Read more →Regulatory Reckoning
A Canceled FDA Meeting Killed an Entire Biotech Company
Kezar Life Sciences didn't die from bad science or a failed trial. It died because the FDA canceled a critical October 2025 meeting and didn't reschedule for four months. By the time the agency showed up in February, investors had fled and the 55-person company was already winding down. The FDA has lost roughly 3,500 positions through layoffs and departures, and over 200 biotech CEOs have signed letters begging Congress to intervene.
Read more →Your Pharmacy Shelf Has a Strait of Hormuz Problem
Commercial shipping through the Strait of Hormuz has collapsed 90% below pre-war levels, and Dubai lost over 10,000 tons of pharmaceutical freight in March alone. No U.S. drug shortages yet, thanks to industry buffers of roughly 180 days. But generic drugmakers on razor-thin margins can't absorb surging rerouting costs forever, and low-income nations are already feeling the squeeze.
Read more →Deals & Markets
Two Pharma Giants Spent Nearly $14 Billion in One Day
Eli Lilly grabbed Centessa Pharmaceuticals for up to $7.8 billion (chasing a narcolepsy drug still in Phase 2), while Biogen paid $5.6 billion for Apellis and its geographic atrophy treatment Syfovre. The biotech index surged on the news, and analysts say pharma giants still have massive acquisition firepower on the sidelines.
Read more →Biotech's IPO Club Now Requires a $300M Cover Charge
Q1 2026 saw just a handful of biotech IPOs, but they raised a record $1.7 billion collectively. The median deal size hit $287.5 million, more than double last year. No preclinical company has gone public since 2024. The message from Wall Street: bring late-stage data and massive backing, or don't bother showing up.
Read more →Science & Pipeline
The Pill That Could End the Obesity Needle Era
Eli Lilly's Foundayo (orforglipron) became the first small-molecule oral GLP-1 approved for obesity, offering 12.4% weight loss in a once-daily pill you can take anytime, no needles or fridge required. Priced at $149 per month (significantly below some injectable list prices), analysts project $1.7 billion in first-year U.S. sales alone.
Read more →A $54M Bet on Getting RNA Out of the Liver
Nearly every RNA drug on the market targets the liver because delivery tech can't reliably reach other organs. Vivatides Therapeutics just raised $54 million in a Series A to crack extrahepatic delivery for siRNA and ASO therapies, targeting kidneys, lungs, and beyond. Whoever solves this problem unlocks a massive expansion of RNA medicine's reach.
Read more →A Stem Cell CEO Jumped Ship for Radioactive Cancer Drugs
Former TreeFrog Therapeutics CEO Frederic Desdouits left cell therapy to run Orano Med, which uses lead-212 isotopes to build targeted alpha therapies for cancer. The move signals growing executive conviction that radiopharmaceuticals are becoming oncology's next major modality.
Read more →